NEW YORK (GenomeWeb News) – Clovis Oncology and Roche today announced a partnership to develop an in vitro PCR-based companion diagnostic test for the identification of activating epidermal growth factor receptor mutations.
The assay, which will run on Roche's cobas 4800 system, is for the identification of mutations, including the EGFR T790M mutation, in patients with non-small cell lung cancer. The test will be for CO-1686, a compound currently in pre-clinical development for advanced NSCLC patients.
CO-1686 is designed to target and covalently bind to the activating T790M mutant forms of EGFR, and was licensed to Clovis from Avila Therapeutics.
"By incorporating a companion diagnostic during clinical and commercial development of CO-1686, we reinforce our commitment to focus development programs on specific subsets of cancer populations that are most likely to benefit from our targeted therapies," Patrick Mahaffy, president and CEO of Boulder, Col.-based Clovis, said in a statement.
Financial and other terms of the deal were not disclosed.